Silver Book Fact

TAVR v. SAVR in Intermediate-Risk SAS Patients

At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical aortic valve replacement (SAVR)), disabling stroke rates of 2.3% (compared to 5.9% for SAVR), and rehospitalization rates of 11.4% (compared to 15.1% for SAVR).

Thourani V, Kodali S, Makkar R, et al. Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Intermediate-Risk Patients: A propensity score analysis. Lancet. 2016; 387(10034): 2218-25. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30073-3/references

Reference

Title
Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Intermediate-Risk Patients: A propensity score analysis
Publication
Lancet
Publication Date
2016
Authors
Thourani V, Kodali S, Makkar R, et al
Volume & Issue
Volume 387, Issue 10034
Pages
2218-25
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • Improvements in QoL from TAVR in SAS patients
    Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state)…  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…